Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy
Pretreatment AMH is a valuable tool for predicting ovarian function resumption after chemotherapy in breast cancer patients, so that a GnRH agonist can be recommended appropriately. However, the predictive value of pretreatment AMH for permanent ovarian insufficiency is too limited to determine the postmenopausal status sufficiently accurately to switch upfront to another endocrine treatment, the aromatase inhibitors.
Authors
- Joop S.E. Laven (ORCID: https://orcid.org/0000-0002-5444-9845)
- Jan C. Drooger
- Yvonne V. Louwers (ORCID: https://orcid.org/0000-0002-9048-7398)
- Annemieke van der Padt‐Pruijsten (ORCID: https://orcid.org/0000-0001-5186-865X)
- Charissa van Zwol-Janssens (ORCID: https://orcid.org/0000-0001-8966-2948)
- Agnes Jager (ORCID: https://orcid.org/0000-0002-7713-1450)
- Mandy M van Rosmalen (ORCID: https://orcid.org/0000-0001-8080-273X)
- Jenny A. Visser (ORCID: https://orcid.org/0000-0001-7182-3571)
- Esther Oomen-de Hoop
- Hanneke Zuetenhorst
Institutions
- Erasmus MC (NL)
- Sint Franciscus Gasthuis (NL)
- Ikazia Ziekenhuis (NL)
- Maasstad Ziekenhuis (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- The Breast
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1016/j.breast.2025.104562
- Citations
- 1
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Pink Ribbon Foundation
- KWF Kankerbestrijding